EA201990395A1 - Варианты комбинированной терапии для лечения рака - Google Patents
Варианты комбинированной терапии для лечения ракаInfo
- Publication number
- EA201990395A1 EA201990395A1 EA201990395A EA201990395A EA201990395A1 EA 201990395 A1 EA201990395 A1 EA 201990395A1 EA 201990395 A EA201990395 A EA 201990395A EA 201990395 A EA201990395 A EA 201990395A EA 201990395 A1 EA201990395 A1 EA 201990395A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- leukemia
- inv
- therapeutically effective
- effective combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000037516 chromosome inversion disease Diseases 0.000 abstract 4
- 208000032839 leukemia Diseases 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000016718 Chromosome Inversion Diseases 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 abstract 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 abstract 1
- 229960004176 aclarubicin Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960001904 epirubicin Drugs 0.000 abstract 1
- 229960000908 idarubicin Drugs 0.000 abstract 1
- 229960001156 mitoxantrone Drugs 0.000 abstract 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367263P | 2016-07-27 | 2016-07-27 | |
| PCT/US2017/044124 WO2018022855A1 (en) | 2016-07-27 | 2017-07-27 | Combination therapies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990395A1 true EA201990395A1 (ru) | 2019-07-31 |
Family
ID=61016782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990395A EA201990395A1 (ru) | 2016-07-27 | 2017-07-27 | Варианты комбинированной терапии для лечения рака |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11241421B2 (https=) |
| EP (1) | EP3490557B1 (https=) |
| JP (1) | JP2019525924A (https=) |
| KR (1) | KR20190032370A (https=) |
| CN (1) | CN109475542A (https=) |
| AU (1) | AU2017302330A1 (https=) |
| BR (1) | BR112019000049A2 (https=) |
| CA (1) | CA3028461A1 (https=) |
| EA (1) | EA201990395A1 (https=) |
| IL (1) | IL263942A (https=) |
| MX (1) | MX2019000179A (https=) |
| WO (1) | WO2018022855A1 (https=) |
| ZA (1) | ZA201900438B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021525280A (ja) | 2018-05-24 | 2021-09-24 | ユニバーシティ オブ バージニア パテント ファウンデーション | がんを治療するための併用療法 |
| CN117567434A (zh) * | 2022-08-08 | 2024-02-20 | 武汉大学 | 靶向CBFβ-SMMHC蛋白的PROTAC类化合物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| WO2006104668A2 (en) | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| CA2614324A1 (en) * | 2005-07-06 | 2007-01-18 | Kanisa Pharmaceuticals, Inc. | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| EP3670509B1 (en) * | 2009-05-13 | 2023-04-19 | University of Virginia Patent Foundation | Inhibitors of inv(16) leukemia |
-
2017
- 2017-07-27 CA CA3028461A patent/CA3028461A1/en not_active Abandoned
- 2017-07-27 EP EP17835254.8A patent/EP3490557B1/en active Active
- 2017-07-27 MX MX2019000179A patent/MX2019000179A/es unknown
- 2017-07-27 BR BR112019000049-6A patent/BR112019000049A2/pt not_active IP Right Cessation
- 2017-07-27 JP JP2019503517A patent/JP2019525924A/ja active Pending
- 2017-07-27 KR KR1020197001728A patent/KR20190032370A/ko not_active Ceased
- 2017-07-27 US US16/318,041 patent/US11241421B2/en active Active
- 2017-07-27 WO PCT/US2017/044124 patent/WO2018022855A1/en not_active Ceased
- 2017-07-27 CN CN201780045352.0A patent/CN109475542A/zh active Pending
- 2017-07-27 AU AU2017302330A patent/AU2017302330A1/en not_active Abandoned
- 2017-07-27 EA EA201990395A patent/EA201990395A1/ru unknown
-
2018
- 2018-12-24 IL IL263942A patent/IL263942A/en unknown
-
2019
- 2019-01-22 ZA ZA201900438A patent/ZA201900438B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475542A (zh) | 2019-03-15 |
| MX2019000179A (es) | 2019-06-20 |
| ZA201900438B (en) | 2019-10-30 |
| JP2019525924A (ja) | 2019-09-12 |
| EP3490557A1 (en) | 2019-06-05 |
| US11241421B2 (en) | 2022-02-08 |
| CA3028461A1 (en) | 2018-02-01 |
| KR20190032370A (ko) | 2019-03-27 |
| AU2017302330A1 (en) | 2019-01-17 |
| US20190343820A1 (en) | 2019-11-14 |
| IL263942A (en) | 2019-02-28 |
| WO2018022855A1 (en) | 2018-02-01 |
| EP3490557B1 (en) | 2022-09-07 |
| EP3490557A4 (en) | 2020-04-01 |
| BR112019000049A2 (pt) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| BR112022008534A2 (pt) | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras | |
| JOP20210171A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| RU2016144668A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2020010676A (es) | Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| EA201990395A1 (ru) | Варианты комбинированной терапии для лечения рака | |
| EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| EA201500579A1 (ru) | Комбинированная терапия с использованием воласертиба | |
| JP2019525924A5 (https=) | ||
| PH12020551493A1 (en) | Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors | |
| EA202190771A1 (ru) | Новое комбинированное решение для лечения рака, резистентного к химиотерапии | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| EA201992500A3 (ru) | Соли и пролекарства 1-метил-d-триптофана |